Abstract

Sodium-glucose cotransporter-2 (SGLT2) inhibitors have revolutionized the management of type 2 diabetes mellitus (T2DM), extending benefits beyond glycaemic control. This review explores the scientific basis, clinical efficacy, real-world applications, and future implications of SGLT2 inhibitors. We discuss cardiovascular and renal benefits, as well as emerging applications in hepatology, neurology, and oncology. Despite robust evidence, the real-world utilization remains suboptimal. This article evaluates perception vs. reality in prescribing practices and highlights the need for more comprehensive patient management strategies.